Dodge & Cox’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $700M | Buy |
5,566,814
+32,190
| +0.6% | +$4.05M | 0.39% | 68 |
|
|
2025
Q1 | $612M | Buy |
5,534,624
+2,518,199
| +83% | +$279M | 0.35% | 77 |
|
|
2024
Q4 | $412M | Buy |
3,016,425
+1,728,605
| +134% | +$236M | 0.24% | 84 |
|
|
2024
Q3 | $148M | Buy |
1,287,820
+7,000
| +0.5% | +$807K | 0.08% | 94 |
|
|
2024
Q2 | $176M | Buy |
1,280,820
+15,576
| +1% | +$2.14M | 0.11% | 90 |
|
|
2024
Q1 | $175M | Buy |
1,265,244
+5,500
| +0.4% | +$759K | 0.1% | 91 |
|
|
2023
Q4 | $166M | Buy |
1,259,744
+1,046,142
| +490% | +$138M | 0.11% | 90 |
|
|
2023
Q3 | $24M | Buy |
+213,602
| New | +$24M | 0.02% | 106 |
|